企業プロフィール
Endra 株価・ニュース・カタリスト
- ティッカー:
- NDRA
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
5.88 USD (-1.34%)
終値
最終更新: 2026年10月1日
9.32M USD
時価総額
株価変動の要因
2026年10月1日 時点で NDRA は 1.34% 下落し、$5.88 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Liver Imaging Technology Company
ENDRA Life Sciences develops thermoacoustic imaging technology for measuring liver fat. Its TAEUS platform is intended to provide a lower-cost, point-of-care alternative to MRI-based quantification.
TAEUS Liver System
TAEUS uses short radiofrequency pulses to stimulate tissue and ultrasound sensors to detect the resulting acoustic response. The system estimates liver fat fraction without ionizing radiation or contrast agents.
MASLD and MASH Monitoring
Quantitative liver-fat measurement can support detection and longitudinal monitoring of metabolic dysfunction-associated steatotic liver disease. ENDRA aims to place this capability in clinics that already use conventional ultrasound.
Clinical Validation Program
The company has conducted feasibility and repeatability studies comparing TAEUS measurements with MRI proton-density fat fraction. Results are being used to refine the device and design a pivotal U.S. clinical study.
De Novo Regulatory Pathway
ENDRA has engaged with the FDA on device configuration, study design, and a De Novo submission pathway. Clearance would be required before broad commercialization in the United States.
今後のカタリスト
- Initiation and completion of the pivotal U.S. study intended to support a De Novo submission for TAEUS Liver.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。